Tuberculosis (TB) is essentially caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) and still a major chronic infectious disease in most parts of the world. Despite applying the various treatment strategies, which were supposed to eliminate this infectious disease from the root, but recent data revealed that TB is once again on the upsurge[@b1]. Worldwide, there is a heavy burden of the disease with 9.6 million new cases and 1.5 million deaths are reported in the year 2014[@b1]. It is assumed that nearly one-third of the world's population is infected with *M. tuberculosis* and fairly large number of population leftover with no clinical symptoms of this infectious disease. However, nearly 5--15% of the individuals will develop the active disease as confirmed by culturable bacilli from the sputum and by other clinical symptoms[@b2]. Therefore, it is assumed that susceptibility and progression to active TB is partly regulated by the host genetic factors[@b3], and this view is consistent with the findings of TB animal models[@b4]. In these infected individuals, the chances of active disease development are based on the immune system's ability to avert the multiplication of dormant *M. tuberculosis*[@b5]. In this regard, the identification of host genes and genetic variations would lead to a better understanding of the pathogenesis of TB and perhaps lead to novel strategies of the treatment or prophylaxis. It is already established that innate immunity is the first line of host defense against TB. At some point during the TB infection cycle, the immunocompetent infected humans will show the presence of mycobacteria and start to generate an immune response, destroying macrophages containing bacilli. This leads to the presentation of mycobacterial antigens to the host immune system, resulting in the generation of a specific immune response against *M. tuberculosis*[@b6].

The *MBL2* gene encodes for mannose-binding lectin (MBL) \[also called mannose-binding protein or mannan-binding protein (MBP)\], is mapped on 10q11.2-q21 chromosome, instrumental in innate immunity via the lectin pathway. MBL is a liver derived complement activating serum lectin, which binds specifically to the oligosaccharide structure present on various microorganisms comprising *M. tuberculosis*, mediates phagocytosis, and activates the mannose-binding lectin pathway of the complement[@b7]. Also, MBL serum concentrations are extremely variable, which are predominantly determined by several single nucleotide polymorphisms (SNPs) in both the coding and regulatory region of the *MBL2* gene[@b8].

Numerous SNPs have been identified in *MBL2* gene, out of which six are acknowledged for their functional effects. Three SNPs are located at exon 1: first, rs5030737 is a C \> T transition at codon 52 (CGT \> TGT) that results in Arg52Cys substitution (where the variant allele is also known as 'D' allele), second, rs1800450 is a G \> A transition (known as 'B' allele) at codon 54 (GGC \> GAC) resulting in Gly54Asp substitution, and third, rs1800451 is a G \> A transition (known as 'C' allele) at codon 57 (GGA \> GAA) resulting in Gly57Glu substitution. These three SNPs are responsible for the disruption of the collagenous back-bone of the MBL molecule and leads to protein dysfunction[@b9]. Collectively, all the three SNPs (rs1800450, rs1800451, rs5030737) are designated as 'AO' polymorphisms and displayed alteration in the serum level of MBL. The wild type allele is designated as allele 'A', and the 'O' mutant allele indicates the presence of one or more mutant allele(s) in any of the three polymorphisms[@b10]. In addition to the exon 1 polymorphisms, there are three more SNPs present in the promoter region and 5′ untranslated region of the *MBL2* gene, *viz.* −550 C \> G (rs11003125, also known as 'HL' variant, where L is the wild type allele), −221 G \> C (rs7096206, 'XY' variant, where Y is the wild type allele) and +4 C \> T (rs7095891, 'PQ' variant, where 'P' is the wild type allele), that can affect the transcription rate, and consequently the concentration of serum MBL. Up to 1000 fold variations in MBL concentration level have been noticed in different individuals possibly because of deviating actions caused due to the combination of structural genes and promoter polymorphisms[@b10].

Since, all the above stated polymorphisms affect *MBL2* gene and lead to low level of the *MBL2* protein, which affects the innate immunity against the pathogen. A number of clinical (case-control) and genetic studies have been done in the past to review the impact of various *MBL2* gene polymorphism on the development of TB[@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32]. The results from the published studies mentioning about the role of *MBL2* gene polymorphisms and genotype on susceptibility to TB infection development are inconsistent and inconclusive. The inconsistency in the results across many of the case-control studies could possibly be due to the ethnicity of the population under consideration, sample size, and low power of the individual studies to determine the overall effect. In order to overcome this issue, nowadays a meta-analysis based statistical tool is in use to evaluate the risk factors associated with the genetic diseases, as it employs a quantitative method of pooling of the data drawn from individual studies, where small sample sizes are insufficient to deliver precise and reliable conclusions. Therefore, the present meta-analysis was performed based on literature identification until 30 March 2016 to evaluate the effect of various *MBL2* polymorphisms, rs1800451 (A \> C), rs1800450 (A \> B), rs5030737 (A \> D), rs7096206 (Y \> X), rs11003125 (H \> L), rs7095891 (P \> Q), and combined rs1800450, rs1800451, rs5030737 (A \> O), on the risk of overall and ethnicity based effect on TB infection.

Results
=======

Characteristics of the published studies
----------------------------------------

The preliminary search of PubMed (Medline), EMBASE and Google Scholar web-databases resulted 52 articles using the selected key words as mentioned in the methods section, and after detailed evaluation of the titles and abstracts, and after eliminating the duplicates, 27 articles dealing with evaluation of the association of *MBL2* polymorphisms and TB risk were screened. After careful reading of the full-text of all the screened articles, 5 studies were disqualified (1 study was omitted as it reported expression analysis; 1 study was excluded due to lack of patients' genotype data; and 3 studies were excluded because of unavailability of genotype distribution). During the study selection, all the retrieved articles were reviewed cautiously, and publications either dealing with *MBL2* variants to predict survival in TB patients or *MBL2* polymorphisms as indicator for response against therapy were disqualified. Likewise, studies pertaining to protein expression or MBL2 mRNA levels or relevant review articles were also omitted from this meta-analysis. In this meta-analysis, only case-control or cohort design studies mentioning the frequency of all the three genotypes were included. In addition to the online database search, the references given in the screened articles were also reviewed for other potential studies. Lastly, after cautious screening and following the pre-set inclusion and exclusion criteria for the selection of the studies, a total of 22 research publications[@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32], showing case-control studies comprising of a total of 7095 confirmed TB patients and 7662 control subjects were included in this pooled analysis ([Fig. 1](#f1){ref-type="fig"} PRISMA Flow-diagram). The major characteristics of the selected studies were abstracted and have been given in [Table 1](#t1){ref-type="table"}. Relevant statistical data of distribution of genotypes, HWE p-values in the controls, and susceptibility towards TB have been presented in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}. In order to improve the overall quality of the meta-analysis, all the 22 studies included in this meta-analysis were subjected for quality assessment following the Newcastle-Ottawa Scale (NOS) and almost all the studies (95%) scored 5 stars or more, indicating a modest to good quality ([Table 4](#t4){ref-type="table"}).

Sensitivity analysis
--------------------

In order to evaluate the effect of each study included in the present meta-analysis, sensitivity analysis was performed for each *MBL2* polymorphism \[rs1800451 (A \> C), rs1800450 (A \> B), rs5030737 (A \> D), Combined rs1800450, rs1800451, rs5030737 (A \> O), rs7096206 (Y \> X), rs11003125 (H \> L), rs7095891 (P \> Q)\] to evaluate the influence of each individual study on the pooled OR by eliminating each single case-control study. The results of sensitivity analysis revealed that no individual study influenced the pooled ORs significantly in all the *MBL2* variants and endorsed the credibility and stability of the present meta-analysis \[[Supplementary Information (SI): Figures SI1--SI7](#S1){ref-type="supplementary-material"}\].

Quantitative synthesis
----------------------

### *MBL2* rs1800450 (A \> B) polymorphism

A total of 14 case-control studies comprising 2795 controls and 2993 confirmed TB cases were incorporated in this part of the analysis and provided sufficient data to calculate ORs. No publication bias was detected, whereas significant heterogeneity was observed in three genetic models ([Table 5](#t5){ref-type="table"}) ([SI: Figure SI8](#S1){ref-type="supplementary-material"}). The pooled ORs revealed that *MBL2* A \> B gene polymorphism is not associated with TB risk in allelic contrast (B vs. A: p = 0.095; OR = 0.901, 95% CI = 0.797 to 1.018), homozygous (BB vs. AA: p = 0.868; OR = 0.820, 95% CI = 0.532 to 1.264), heterozygous (AB vs. AA: p = 0.203; OR = 0.872, 95% CI = 0.706 to 1.077), dominant (BB + AB vs. AA: p = 0.484; OR = 1.166, 95% CI = 0.759 to 1.789), and recessive (BB vs. AA + AB: p = 0.249; OR = 0.878, 95% CI = 0.703 to 1.095) genetic models ([Fig. 2](#f2){ref-type="fig"}).

### *MBL2* rs1800451 (A \> C) polymorphism

A total of 11 case-control studies containing 4535 controls and 4352 confirmed TB cases were included in this pooled study of *MBL2* A \> C and TB risk, and delivered sufficient data to calculate ORs. Publication bias did not exist and heterogeneity was found in two genetic models ([Table 6](#t6){ref-type="table"}) ([SI: Figure SI9](#S1){ref-type="supplementary-material"}). The pooled ORs revealed that homozygous (CC vs. AA: p = 0.045; OR = 0.834, 95% CI = 0.699 to 0.996) genetic model of *MBL2* A \> C gene polymorphism is associated with reduced risk of TB ([Fig. 3](#f3){ref-type="fig"}). Whereas, other genetic models, i.e., allelic contrast (C vs. A: p = 0.076; OR = 0.936, 95% CI = 0.869 to 1.007), heterozygous (CA vs. AA: p = 0.994; OR = 0.999, 95% CI = 0.827 to 1.208), dominant (AA + AC vs. CC: p = 0.089; OR = 1.159, 95% CI = 0.978 to 1.374), and recessive (AA vs. CC + AC: p = 0.811; OR = 0.978, 95% CI = 0.818 to 1.170) models did not show any association with TB risk ([Fig. 3](#f3){ref-type="fig"}).

### *MBL2* rs5030737 (A \> D) polymorphism

The pooled analysis for *MBL2* A \> D polymorphism with TB susceptibility involved 8 case-control studies including 1191 controls and 1589 confirmed TB cases, and resulted sufficient data to calculate ORs. Publication bias and heterogeneity were not detected during the analysis ([Table 7](#t7){ref-type="table"}) ([SI: Figure SI10](#S1){ref-type="supplementary-material"}). The pooled ORs revealed that *MBL2* A \> D gene polymorphism was not associated with TB risk in allelic contrast (D vs. A: p = 0.396; OR = 1.141, 95% CI = 0.842 to 1.546), homozygous (DD vs. AA: p = 0.190; OR = 2.592, 95% CI = 0.623 to 10.780), heterozygous (AD vs. AA: p = 0.859; OR = 0.971, 95% CI = 0.700 to 1.346), dominant (AA + AD vs. DD: p = 0.194; OR = 0.389, 95% CI = 0.094 to 1.616), and recessive (AA vs. DD + AD: p = 0.728; OR = 1.058, 95% CI = 0.770 to 1.454) genetic models ([Fig. 4](#f4){ref-type="fig"}).

### *MBL2* combined rs1800450, rs1800451, rs5030737 (A \> O) exon 1 polymorphism

In this analysis, a total of 10 case-control studies involving 2040 control subjects and 1945 confirmed TB cases were taken into consideration and provided sufficient data to calculate ORs. No publication bias was found during the analysis, while, heterogeneity was detected in all the genetic models ([Table 8](#t8){ref-type="table"}) ([SI: Figure SI11](#S1){ref-type="supplementary-material"}). The pooled ORs of this analysis revealed that combined A \> O exon 1 polymorphism is not associated with TB in allelic contrast (O vs. A: p = 0.150; OR = 1.303, 95% CI = 0.909 to 1.869), homozygous (OO vs. AA: p = 0.076; OR = 2.246, 95% CI = 0.920 to 5.483), heterozygous (AO vs. AA: p = 0.289; OR = 1.224, 95% CI = 0.842 to 1.779), dominant (OO + AO vs. AA: p = 0.061; OR = 0.504, 95% CI = 0.246 to 1.033), and recessive (OO vs. AA + AO: p = 0.194; OR = 1.321, 95% CI = 0.868 to 2.011) genetic models ([Fig. 5](#f5){ref-type="fig"}).

### *MBL2* rs7096206 (Y \> X) polymorphism

In this analysis, a total of 7 case-control studies (3774 controls & 3379 confirmed TB cases) provided needful data to estimate ORs. Publication bias did not exist, and heterogeneity was found in three genetic models ([Table 9](#t9){ref-type="table"}) ([SI: Figure SI12](#S1){ref-type="supplementary-material"}). The pooled ORs revealed that combined gene polymorphism was not associated with TB in allelic contrast (X vs. Y: p = 0.247; OR = 1.124, 95% CI = 0.922 to 1.370), homozygous (XX vs. YY: p = 0.514; OR = 0.900, 95% CI = 0.655 to 1.235), heterozygous (YX vs. XX: p = 0.095; OR = 1.235, 95% CI = 0.964 to 1.582), dominant (YY + YX vs. XX: p = 0.389; OR = 1.148, 95% CI = 0.839 to 1.573) and recessive (YY vs. XX + YX: p = 0.142; OR = 1.198, 95% CI = 0.941 to 1.526) genetic models ([Fig. 6](#f6){ref-type="fig"}).

### *MBL2* rs11003125 (H \> L) polymorphism

For analyzing the correlation of *MBL2* H \> L gene polymorphism with TB risk, the abstracted data from 4 case-control studies involving 2989 controls and 2290 confirmed TB cases were included to calculate ORs. Publication bias did not exist, while heterogeneity was found in two genetic models ([Table 10](#t10){ref-type="table"}) ([SI: Figure SI13](#S1){ref-type="supplementary-material"}). The pooled ORs demonstrated that *MBL2* H \> L gene polymorphism is not associated with TB risk in allelic contrast (L vs. H: p = 0.757; OR = 1.019, 95% CI = 0.904 to 1.149), homozygous (LL vs. HH: p = 0.561; OR = 0.907, 95% CI = 0.653 to 1.260), heterozygous (HL vs. LL: p = 0.651; OR = 0.905, 95% CI = 0.588 to 1.394), dominant (HH + HL vs. LL: p = 0.491; OR = 0.915, 95% CI = 0.710 to 1.179), and recessive (HH vs. LL + HL: p = 0.742; OR = 0.935, 95% CI = 0.626 to 1.396) genetic models ([Fig. 7](#f7){ref-type="fig"}).

### *MBL2* rs7095891 (P \> Q) polymorphism

In order to study the influence of *MBL2* P \> Q gene polymorphism on TB susceptibility, this analysis was done by including 3 case-control studies involving 2895 controls and 2245 confirmed TB cases that provided the required data for the calculation of ORs. No publication bias and heterogeneity were found among all the genetic models ([Table 11](#t11){ref-type="table"}) ([SI: Figure SI14](#S1){ref-type="supplementary-material"}). The pooled ORs showed that *MBL2* P \> Q gene polymorphism was not associated with TB susceptibility in allelic contrast (Q vs. P: p = 0.679; OR = 1.018, 95% CI = 0.935 to 1.109), homozygous (QQ vs. PP: p = 0.321; OR = 1.098, 95% CI = 0.913 to 1.320), heterozygous (PQ vs. PP: p = 0.426; OR = 0.950, 95% CI = 0.839 to 1.077), dominant (QQ + PQ vs. PP: p = 0.185; OR = 0.892, 95% CI = 0.753 to 1.056), and recessive (QQ vs. PP + PQ: p = 0.725; OR = 0.979, 95% CI = 0.869 to 1.102) genetic models ([Fig. 8](#f8){ref-type="fig"}).

Subgroup stratification analysis
--------------------------------

Subgroup stratification analysis by the ethnicity of the subjects' (studies') origin was performed to examine the impact of potential genetic variation on an individual's risk of TB. The subgroup ethnicity analysis was performed when four or more case-control studies (for meaningful statistical significance) of *MBL2* polymorphisms were present in any ethnicity group. Also, only significant data have been presented here in this manuscript for all the *MBL2* polymorphisms.

As the *MBL2* combined rs1800450, rs1800451, rs5030737 (A \> O) exon 1 polymorphism was reported by only three studies each from Asian, Caucasian and Mixed population, so, we failed to include those studies for the subgroup stratification analysis. Likewise, *MBL2* rs11003125 (H \> L) polymorphism was reported from only two studies of Asian population and one study each of African and Mixed populations, hence we were unable to include those studies for subgroup stratification analysis. Similarly, *MBL2* rs5030737 (out of total eight studies, three each were from African and Mixed population, and two were from Asian population) and rs7095891 (out of total three studies, two were from Asian population and one was from African population) polymorphisms were not considered for the subgroup stratification analysis due to unavailability of sufficient number of studies.

### Subgroup stratification analysis for MBL2 rs1800450

Among the two different ethnic subgroups, Asian and African, the subgroup analysis showed no publication bias and heterogeneity among all the genetic models of African population ([SI: Table ST1](#S1){ref-type="supplementary-material"}), whereas, publication bias and heterogeneity were noticed in some genetic models of Asian population ([SI: Table ST2](#S1){ref-type="supplementary-material"}). The subgroup analysis demonstrated reduced risk under the allele (B vs. A: p = 0.009; OR = 0.672, 95% CI = 0.499 to 0.905), heterozygous (AB vs. AA: p = 0.006; OR = 0.639, 95% CI = 0.465 to 0.878) and dominant (BB vs. AA + AB: p = 0.006; OR = 0.644, 95% CI = 0.470 to 0.881) genetic models of African population ([Fig. 9](#f9){ref-type="fig"}). But, no significant associations were found in case of Asian population ([Fig. 10](#f10){ref-type="fig"}). The subgroup stratification analysis by the ethnicity was not performed for Caucasian and Mixed populations because only three studies were found from these two populations for *MBL2* rs1800450 gene variant.

### Subgroup stratification analysis for MBL2 rs1800451

In this subgroup stratification analysis, for African population, the variant C allele was associated with decreased TB risk in allele (C vs. A: p = 0.041; OR = 0.925, 95% CI = 0.858 to 0.997) and homozygous (CC vs. AA: p = 0.044; OR = 0.833, 95% CI = 0.697 to 0.995) genetic models ([Fig. 11](#f11){ref-type="fig"}). Also, no publication bias and heterogeneity were found in all the genetic models of African population ([SI: Table ST3](#S1){ref-type="supplementary-material"}). As only two studies were reported from Asian and three studies were originated from Mixed population, so we have not considered those studies for the ethnicity analysis.

### Subgroup stratification analysis for MBL2 rs7096206

A total of five studies were included from Asian population for *MBL2* rs7096206 polymorphism. In this analysis, no publication bias was observed but heterogeneity was found in three genetic models of Asian population ([SI: Table ST4](#S1){ref-type="supplementary-material"}). Overall, no significant association was found in all the five genetic models ([Fig. 12](#f12){ref-type="fig"}). Due to lack of sufficient number of reports (only one in each ethnicity group) from African and Mixed population, studies dealing with these two populations were not considered for the subgroup stratification analysis.

Discussion
==========

Numerous epidemiological reports have strongly suggested the influence of genetic factors on the development of TB[@b33]. Likewise, earlier studies have used population based design with candidate genes of immunological pathways for their implication in TB susceptibility. Some proteins involved in innate immunity such as the MBL protein, can recognizes the mannose present on the surface of pathogens, and promotes both the opsonization and activation of the complement system. As, MBL is a calcium-dependent plasma collagenous lectin, thus plays a significant role in innate immune defense against infectious agents[@b34]. The gene product of MBL2 i.e., mannose-binding lectin, binds to mannose groups present on a variety of bacteria. MBP-mycobacterial complexes offer a vehicle for the dissemination by increasing the uptake through macrophages as they migrate in the blood. MBP has been shown to bind and opsonize mycobacteria, and subsequent enhanced uptake by phagocytes[@b35]. Further studies also reported that phosphatidylinositol mannoside of *M. tuberculosis* has been shown to bind with human MBP[@b36]. As, the cell wall of *M. tuberculosis* contains lipoarabinomannan (LAM), hence it has been suggested that MBP could act as a type of binding protein for mycobacteria and facilitate their entrance in the host macrophages.

Since, both the acquired and innate-immunities contribute to the killing of *M. tuberculosis*, but the precise mechanism that provide resistance against the infection has not been deciphered completely. In recent years, a number of studies have been carried out to assess exon 1, promoter, and 5′ untranslated region polymorphisms of *MBL2* gene, but their results are inconsistent. The conflicting results generated by the earlier studies may have insufficient statistical power possibly due to small sample size of the individual studies or variations that existed in different ethnicities. Therefore, in order to address the above stated limitations of the earlier case-control studies, the present meta-analysis was performed to provide a more precise statistical evidence of the association between various polymorphisms of *MBL2* gene and TB susceptibility, as the pooled ORs generated from the large sample size and sufficient statistical power from various studies have the advantage of minimizing the random errors[@b37].

In this study, a total of 22 case-control studies were included for the meta-analysis which were fulfilling the pre-set eligibility criteria of the study inclusion. All the included studies clearly mentioned about the sample size, genotype, inclusion criteria of confirmed TB patients and healthy controls. We found that homozygous variant allele of rs1800451 (A \> C) polymorphism was significantly associated with reduced risk of TB ([Fig. 3](#f3){ref-type="fig"}). This indicates that individual's carrier of homozygous genotype may be one of the factors that prevents TB patients in general population. Homozygous variant might produce low level of MBP and help the host in fighting with the infection and prevent the TB risk by showing the protective effect. These outcomes support the report of Garred *et al*.[@b38], which suggests that the high frequency of MBP variant alleles in many populations might be due to higher resistance to mycobacteria[@b38]. However, this view requires further replications in other studies.

On the other hand, genetic models of other *MBL2* polymorphisms, i.e., rs1800450 (A \> B), rs5030737 (A \> D), combined polymorphisms (rs1800450, rs1800451, rs5030737: A \> O), rs7096206 (Y \> X), rs11003125 (H \> L), rs7095891 (P \> Q) were not showing any association with increased or decreased risk of TB. Earlier, Denholm *et al*.[@b39], performed the meta-analysis of *MBL2* gene polymorphisms and TB susceptibility, and reported no definite and consistent association between *MBL2* genotypes and TB infection[@b39]. Also, the study of Denholm *et al*.[@b39], has certain limitations, as many of the included studies did not report a complete *MBL2* genotype[@b39]. When the data were stratified by the ethnicity for the subgroup analysis, the results demonstrated that *MBL2* rs1800450 and rs1800451 polymorphisms had a protective effect of TB in African population. The subgroup analysis by the ethnicity also revealed that the strength of the association of *MBL2* polymorphisms with TB risk varied greatly across various ethnic groups. This suggests the presence of significant differences in the genetic backgrounds of different ethnic populations.

There is an emerging evidence that *M. tuberculosis* strains are genetically heterogeneous (in comparison to the previously established thought) and are correlated with specific geographical (based upon the ethnicity) areas[@b40][@b41]. With the passage of time, host and *M. tuberculosis* co-evolved, and individual strains are now adapted to their own specific populations[@b42]. It is evident from the previous studies that the risk of TB is polygenic and various genes are involved in the susceptibility of *M. tuberculosis* infection[@b43]. Hence, it might be possible that only *MBL2* gene polymorphisms could not be solely accountable for the predisposition of TB infection.

In the present study, significant heterogeneity was found between some of the selected studies in the test of heterogeneity. The occurrence of discord among the selected studies is possibly related to the ethnic origin of the included TB patients as ethnicity-specific genetic variations may influence the host immunity to TB infection. In addition to some concrete findings, there are some limitations associated with the present meta-analysis that need to be addressed in the future studies. First, we only included research articles published in the English language, abstracted and indexed by the specific electronic databases; it is possible that some relevant research articles appeared in other languages and indexed in some other databases may have missed. Second, the abstracted data from the included studies were not stratified by other relevant factors, such as severity of the TB infection or HIV status, and our current findings are established on unadjusted parameters. Third, we did not check for gene and environment interactions due to lack of sufficient information in the primary included studies. And, fourth, meta-analysis remains a retrospective research that is subjected to the methodological insufficiencies or selection bias of the primary included studies and may perhaps deviate or influence the reliability of the results.

Regardless of the above stated limitations, there are some advantages associated with this meta-analysis. First, this meta-analysis included more number of studies in comparison to the previously published pooled analysis, with increased statistical power and resulted statistically significant and robust conclusion. Second, publication bias did not detect. Also, the supplementary sensitivity analysis supported that the results of the present meta-analysis are reliable.

We conclude that meta-analysis is a powerful tool and gives a consensus answer using available data from different individual studies. The overall output of a meta-analysis is more precise as all the individual data is clustered during the analysis. Our result demonstrated that *MBL2* rs1800451 and rs1800451 gene polymorphisms play a protective role against the development of TB disease and might be a good candidate genetic marker for TB risk. In the near future, because of the significant public health impact of TB, definite concept, role, and mechanism of *MBL2* gene in during infection and replication of *M. tuberculosis* studies are warranted. This will assist in making complete genotype profile of the *MBL2* gene for TB susceptibility, and would significantly help in the global control and outcome of this infectious disease. Also, more comprehensive studies with group of populations considering environmental factors and HIV status are warranted to re-evaluate the associations of these *MBL2* SNPs with other gene polymorphisms in relevance with TB risk.

Materials and Methods
=====================

Literature search strategy
--------------------------

A systematic search for the pertinent studies was performed using the online databases, PubMed (Medline), EMBASE and Google Scholar covering all the research articles published with a combination of the given key words, i.e., 'Mannose binding lectin OR *MBL2* OR MBL OR Mannose binding protein OR MBP' gene (polymorphism OR mutation OR variant) AND tuberculosis OR TB susceptibility/risk (last updated on March 2016). We examined the potentially relevant genetic association studies by reading their titles and abstracts, and screened the most germane publication matching with the pre-set eligible criteria for a closer investigation. In addition to the web-database search, the references given in the screened research articles were also checked for other potential publications that may have been missed in the preliminary search. The search in above mentioned web-databases was only restricted to publications relating to humans.

Inclusion and exclusion criteria
--------------------------------

The identified studies in this meta-analysis had to meet all of the below given criteria to reduce heterogeneity and facilitate the apt interpretation of this study: (a) they must have evaluated unrelated case-control studies or cohort design between *MBL2* gene polymorphisms \[rs1800451 (A \> C), rs1800450 (A \> C), rs5030737 (A \> D), rs7096206 (Y \> X), rs11003125 (H \> L), rs7095891 (P \> Q), and combined rs1800450, rs1800451, rs5030737 (A \> O)\] and TB risk, (b) should clearly designated confirmed TB patients and TB free controls, (d) have available genotype frequency in both the cases and controls to calculate odds ratio (OR) and 95% confidence interval (CI), (e) independent studies showing original data, (f) published in the English language, (g) followed statistically acceptable data collection and analysis methodology. Moreover, when the case-control study was involved in more than one research publication using the same case series, the research study that incorporated the highest number of individuals was included in this analysis. The studies were excluded based upon the following criteria: (a) duplicated or overlapping publication, (b) study design based on only TB cases, (c) without genotype distribution or allele frequency data, (d) clinical case studies without control subjects, (e) data of review, abstracts, or case reports.

Data extraction
---------------

The methodological quality evaluation and data extraction were independently performed in duplicate copies by two independent investigators (RKM & NA) using a standard process for each retrieved article, based on the pre-set eligibility criteria of the study inclusion in the present study, and sequential exclusion of the inappropriate studies. In order to confirm the accuracy of the abstracted data by strictly following the given selection criteria a standard data-collection form was used. The following data were abstracted from each included study: publication year, the name of first author, origin country, ethnicity, source of cases and controls, number of cases and controls, type of TB \[pulmonary TB (PTB) or extra-pulmonary TB (EPTB)\], study type, genotype frequencies, *MBL2* polymorphisms, and reported associations. Cases of disagreement or discrepancy in any item of the abstracted data from the selected articles were resolved by conducting group discussions involving adjudicator (SAD) to accomplish a final consensus.

Quality assessment of the selected studies
------------------------------------------

The Newcastle-Ottawa quality assessment Scale (NOS)[@b44] was used independently by the two authors (RKM and NA) to evaluate the overall quality of the included studies. The NOS criteria involved three points: (1) subject selection: 0--4 points; (2) comparability of subject: 0--2 points; and (3) clinical outcome: 0--3 points. Studies scoring 5 or more stars were considered to be of moderate to high quality[@b44]. In order to maintain the overall quality of the meta-analysis by using NOS quality assessment, any disagreement was thoroughly discussed, and another author (adjudicator: SAD) was consulted.

Statistical analysis
--------------------

Pooled ORs and their corresponding 95% CIs were calculated to appraise the association of *MBL2* gene polymorphisms with the risk of developing TB. Chi-square-based Q-test was applied to test the heterogeneity assumption[@b45], and it was considered significant at p-value \< 0.05. In case of no heterogeneity, the data from single comparison was pooled by applying a fixed effects model[@b46]. Or else (in case of significant heterogeneity), the random-effects model was applied for the pooling of the data[@b47]. Also, I^2^ statistics was used to measure inter-study variability, and greater values indicated higher degree of heterogeneity[@b48]. Chi-square test was adopted to estimate the Hardy-Weinberg equilibrium (HWE) in the control group. Publication bias was appraised by checking the Begg's funnel plots[@b49] and Egger's linear regression test[@b50]. The asymmetry of the funnel plot was measured by Egger's regression test (a linear regression method of measuring the funnel plot asymmetry on the natural logarithm scale of the OR) and the significance of the intercept was calculated by the t-test. Statistically significant publication bias was considered at p-value \< 0.05. All the software programs featuring 'meta-analysis' tools were compared by using the web-link: <https://www.meta-analysis.com/pages/comparisons.php>, and finally Biostat's (NJ, USA) Comprehensive Meta-Analysis (CMA) Version 2 program was selected for performing all the statistical study involved in this meta-analysis.
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![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs1800450 (A \> B) gene polymorphism for overall population.\
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![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs1800451 (A \> C) gene polymorphism for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f3){#f3}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs5030737 (A \> D) gene polymorphism for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f4){#f4}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* combined rs1800450, rs1800451, rs5030737 (A \> O) exon 1 gene polymorphisms for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f5){#f5}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs7096206 (Y \> X) gene polymorphism for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f6){#f6}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs11003125 (H \> L) gene polymorphism for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f7){#f7}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs7095891 (P \> Q) gene polymorphism for overall population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f8){#f8}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs1800450 (A \> B) gene polymorphism for African population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f9){#f9}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs1800450 (A \> B) gene polymorphism for Asian population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f10){#f10}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs1800451 (A \> C) gene polymorphism for African population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f11){#f11}

![Forest plot of ORs with 95% CI of TB risk associated with the *MBL2* rs7096206 (Y \> X) gene polymorphism for Asian population.\
Black square represents the value of OR and the size of the square indicates the inverse proportion relative to its variance. Horizontal line is the 95% CI of OR.](srep35728-f12){#f12}

###### Main characteristics of all studies included in the meta-analysis.

  First author & Ref. No.      Study Type     Country      Ethnicity   Control   Cases         Type                    *MBL2* gene variants/SNPs                   Methods            Association
  --------------------------- ------------ -------------- ----------- --------- ------- ------------------- ------------------------------------------------ ------------------- ---------------------
  Wu *et al*.[@b11]                CC          China         Asian       453      151           PTB                  P \> Q, Y \> X, H \> L, A \> B               PCR-RFLP                No
  Chen *et al*.[@b12]              CC          China         Asian       419      503           TB                              Y \> X,                            PCR-SSP                Yes
  Chen *et al*.[@b13]              CC          China         Asian       216      205           TB                              Y \> X,                            PCR-SSP                Yes
  Garcia *et al*.[@b14]            CC          Spain       Caucasian     106      76         PTB, EPTB                           A \> O                            PCR-SSP                No
  Heidi *et al*.[@b15]             CC          Brazil        Mixed       148      155        PTB, EPTB       H \> L, Y \> X, A \> O, A \> D, A \> B, A \> C      Sequencing       A \> O, A \> C risk
  Araujo *et al*.[@b16]            CC          Brazil        Mixed       159      167        PTB, EPTB               A \> B, A \> C, A \> D, A \> O                  PCR                  No
  Singla *et al*.[@b17]            CC          India         Asian       392      357        PTB, EPTB                           A \> B                           PCR-RFLP                Yes
  Thye *et al*.[@b18]              CC          Ghana        African     2346     2230           PTB                  H \> L, Y \> X, P \> Q, A \> C            Pyrosequencing           A \> C
  de Wit *et al*.[@b19]            CC       South Africa    African      318      505           TB                        A\>B, A \> D, A \> C                PCR-RFLP ARMS-PCR           No
  Capparelli *et al*.[@b20]        CC          Italy       Caucasian     288      277           PTB                              A \> O                              PCR              Protective
  Cossar *et al*.[@b21]            CC          Turkey      Caucasian     44       99         PTB, EPTB                           A \> B                           PCR-RFLP            Protective
  Alagarasu *et al*.[@b22]         CC          India         Asian       146      366     HIV + PTB, EPTB        A \> B, A \> D, A \> C, A \> O, Y \> X            PCR-SSP          Y \> X, A \> O
  Soborg *et al*.[@b23]            CC         Tanzania      African      426      443           PTB                  A \> B, A \> D, A \> C, A \> O               PCR-RFLP                No
  Liu *et al*.[@b24]               CC          China         Asian       293      152           PTB                  H \> L, P \> Q, Y \> X, A \> B                PCR-SSP                No
  Garcia *et al*.[@b25]            CC          Spain       Caucasian     344      127           TB                               A \> O                       PCR-RFLP PCR-SSP            No
  Selvaraj *et al*.[@b26]          CC          India         Asian       58       48            PTB                              A \> O                           PCR-SSOP                No
  Fitness *et al*.[@b27]           CC          Malawi       African      546      322         HIV+−TB                            A \> C                        F-PCR ARMS-PCR             Yes
  Soborg *et al*.[@b28]            CC         Denmark        Mixed       250      109           TB                   A \> O, A \> B, A \> D, A \> C                PCR-SSP                No
  Ozbaş *et al*.[@b29]             CC          Turkey      Caucasian     100      49            PTB                              A \> B                              PCR                  No
  Selvaraj *et al*.[@b30]          CC          India         Asian       109      202           PTB                  A \> B, A \> C, A \> D, A \> O                  PCR                A \> C
  Hoal *et al*.[@b31]              CC       South Africa    African      79       155    PTB, Meningeal TB               A \> B, A \> C, A \> D                   PCR-RFLP         Protective A \> B
  Bellamy *et al*.[@b32]           CC          Gambia       African      422      397           PTB                          A \> B, A \> C                          PCR           Protective A \> C

Note: \**MBL2* gene variants designated as: rs1800451 (A \> C), rs1800450 (A \> B), rs5030737 (A \> D), rs7096206 (Y \> X), rs11003125 (H \> L), rs7095891 (P \> Q), Combined rs1800450, rs1800451, rs5030737 (A \> O).

**\*\***CC = Case-control study; TB = Tuberculosis; PTB = Pulmonary tuberculosis; EPTB = Extrapulmonary tuberculosis; HIV = Human immunodeficiency virus.

###### Genotypic distribution of *MBL2* gene polymorphisms included in this meta-analysis.

  First author & Ref. no.            Controls                  Cases             HWE                                             
  -------------------------- ------------------------ ------------------------ -------- ------ -------- -------- -------- ------ -------
  Wu *et al*.[@b11]                    348                       97               8      0.12    112       37       2      0.13   0.681
  Heidi *et al*.[@b15]                 124                       21               3      0.09    122       31       2      0.11   0.079
  Araujo *et al*.[@b16]                101                       48               0      0.16    102       50       0      0.16   0.190
  Singla *et al*.[@b17]                207                      155               30     0.27    218      126       13     0.21   0.895
  De wit *et al*.[@b19]                211                       50               0      0.09    363       63       2      0.07   0.087
  Cossar *et al*.[@b21]                 71                       27               1      0.14     40       4        0      0.04   0.366
  Alagarasu *et al*.[@b22]              86                       33               4      0.16    212       65       16     0.16   0.704
  Soborg *et al*.[@b23]                271                       13               1      0.02    289       9        0      0.01   0.063
  Liu *et al*.[@b24]                   166                       42               4      0.11    103       34       4      0.14   0.487
  Soborg *et al*.[@b28]                157                       48               3      0.12     71       16       3      0.12   0.756
  Ozbaş *et al*.[@b29]                  76                       20               4      0.14     40       9        0      0.09   0.090
  Selvaraj *et al*.[@b30]               84                       24               1      0.11    137       51       14     0.19   0.615
  Hoal *et al*.[@b31]                   46                       21               1      0.16    114       16       1      0.06   0.414
  Bellamy *et al*.[@b32]               183                       5                0      0.01    198       7        0      0.01   0.853
                              **Genotype rs1800451**   **Genotype rs1800451**                                                    
                                      **AA**                   **AC**           **CC**          **AA**   **AC**   **CC**             
  Heidi *et al*.[@b15]                 140                       8                0      0.02    133       22       0      0.07   0.735
  Araujo *et al*.[@b16]                101                       2                0      0.00    102       4        0      0.01   0.920
  Thye et al.[@b18]                    1002                     977              257     0.33    885      815      194     0.31   0.421
  De wit *et al*.[@b19]                211                       39               0      0.07    363       56       0      0.06   0.181
  Alagarasu *et al*.[@b22]              86                       12               1      0.07    212       20       1      0.04   0.439
  Soborg *et al*.[@b23]                271                      112               20     0.18    289      115       20     0.18   0.065
  Fitness *et al*.[@b27]               362                      160               24     0.19    205      105       12     0.20   0.244
  Soborg *et al*.[@b28]                157                       13               0      0.03     71       2        1      0.02   0.604
  Selvaraj *et al*.[@b30]              103                       5                1      0.03    176       25       1      0.06   0.006
  Hoal *et al*.[@b31]                   46                       8                0      0.07    114       23       0      0.08   0.556
  Bellamy *et al*.[@b32]               183                      192               42     0.33    198      159       29     0.28   0.417
                              **Genotype rs5030737**   **Genotype rs5030737**                                                    
                                      **AA**                   **AD**           **DD**          **AA**   **AD**   **DD**             
  Heidi *et al*.[@b15]                 138                       9                1      0.03    142       12       1      0.04   0.067
  Araujo *et al*.[@b16]                101                       6                0      0.02    102       8        0      0.03   0.765
  De wit *et al*.[@b19]                211                       13               0      0.02    363       15       0      0.01   0.654
  Alagarasu *et al*.[@b22]              86                       8                0      0.04    212       33       3      0.07   0.666
  Soborg *et al*.[@b23]                271                       6                0      0.01    289       8        0      0.01   0.855
  Soborg *et al*.[@b28]                157                       25               1      0.07     71       12       1      0.08   0.996
  Selvaraj *et al*.[@b30]               99                       10               0      0.04    186       9        7      0.05   0.615
  Hoal *et al*.[@b31]                   46                       3                0      0.03    114       1        0      0.00   0.825

MAF, Minor allele frequency, HWE, Hardy Weinberg Equilibrium.

###### Genotypic distribution of *MBL2* gene polymorphisms included in this meta-analysis.

  First author & Ref. no.             Controls                    Cases             HWE                                             
  --------------------------- ------------------------- ------------------------- -------- ------ -------- -------- -------- ------ -------
  Garcia *et al*.[@b14]                  71                        34                1      0.16     48       24       4      0.21   0.156
  Heidi *et al*.[@b15]                   108                       34                6      0.15     92       55       8      0.22   0.128
  Araujo *et al*.[@b16]                  101                       56                2      0.18    102       62       3      0.20   0.057
  Capparelli *et al*.[@b20]              166                       112               10     0.22     55      158       61     0.51   0.087
  Alagarasu *et al*.[@b22]               86                        53                7      0.22    212      121       32     0.25   0.747
  Soborg *et al*.[@b23]                  271                       131               30     0.22    289      132       22     0.19   0.030
  Garcia *et al*.[@b25]                  183                       134               27     0.27     70       33       3      0.18   0.721
  Selvaraj *et al*.[@b26]                37                        18                3      0.20     24       19       5      0.30   0.678
  Soborg *et al*.[@b28]                  157                       86                7      0.20     71       30       8      0.21   0.235
  Selvaraj *et al*.[@b30]                68                        39                2      0.19    107       73       22     0.28   0.175
                               **Genotype rs7096206**    **Genotype rs7096206**                                                     
                                       **YY**                    **YX**            **XX**          **YY**   **YX**   **XX**             
  Wu *et al*.[@b11]                      318                       120               15     0.16     97       47       7      0.20   0.379
  Chen *et al*.[@b12]                    296                       113               10     0.15    325      166       12     0.18   0.839
  Chen *et al*.[@b13]                    159                       49                8      0.15    123       77       5      0.21   0.097
  Heidi *et al*.[@b15]                   110                       32                6      0.14    101       49       5      0.19   0.076
  Thye *et al*.[@b18]                   1663                       486               31     0.12    1437     396       26     0.12   0.502
  Alagarasu *et al*.[@b22]               72                        61                13     0.29    218      133       14     0.22   0.987
  Liu *et al*.[@b24]                     151                       54                7      0.16     91       44       6      0.19   0.430
                               **Genotype rs11003125**   **Genotype rs11003125**                                                    
                                       **HH**                    **HL**            **LL**          **HH**   **HL**   **LL**             
  Wu *et al*.[@b11]                      101                       248              104     0.50     46       64       41     0.48   0.043
  Heidi *et al*.[@b15]                   19                        61                68     0.66     10       63       82     0.73   0.366
  Thye *et al*.[@b18]                   1878                       289               9      0.07    1570     266       7      0.07   0.550
  Liu *et al*.[@b24]                     49                        105               58     0.52     44       66       31     0.45   0.911
                               **Genotype rs7095891**    **Genotype rs7095891**                                                     
                                       **PP**                    **PQ**            **QQ**          **PP**   **PQ**   **QQ**             
  Wu *et al*.[@b11]                      364                       87                2      0.10    124       26       1      0.09   0.181
  Thye *et al*.[@b18]                    825                      1086              319     0.38    725      920      308     0.39   0.204
  Liu *et al*.[@b24]                     171                       39                2      0.10    118       22       1      0.08   0.891

MAF, Minor allele frequency, HWE, Hardy Weinberg equilibrium.

###### Quality assessment conducted according to the Newcastle-Ottawa Scale for all the included studies.

  First author and Ref. no.    Quality indicators       
  --------------------------- -------------------- ---- --------
  Wu *et al*.[@b11]                  \*\*\*         \*    \*\*
  Chen *et al*.[@b12]                \*\*\*         \*   \*\*\*
  Chen *et al*.[@b13]                \*\*\*         \*   \*\*\*
  Garcia *et al*.[@b14]               \*\*          \*    \*\*
  Heidi *et al*.[@b15]               \*\*\*         \*    \*\*
  Araujo *et al*.[@b16]              \*\*\*         \*    \*\*
  Singla *et al*.[@b17]              \*\*\*         \*   \*\*\*
  Thye *et al*.[@b18]               \*\*\*\*        \*   \*\*\*
  de Wit *et al*.[@b19]              \*\*\*         \*    \*\*
  Capparelli *et al*.[@b20]          \*\*\*         \*    \*\*
  Cossar *et al*.[@b21]               \*\*          \*    \*\*
  Alagarasu *et al*.[@b22]           \*\*\*         \*     \*
  Soborg *et al*.[@b23]              \*\*\*         \*     \*
  Liu *et al*.[@b24]                 \*\*\*         \*   \*\*\*
  Garcia *et al*.[@b25]             \*\*\*\*        \*    \*\*
  Selvaraj *et al*.[@b26]            \*\*\*         \*     \*
  Fitness *et al*.[@b27]            \*\*\*\*        \*    \*\*
  Soborg *et al*.[@b28]              \*\*\*         \*    \*\*
  Ozbaş *et al*.[@b29]                 \*           \*    \*\*
  Selvaraj *et al*.[@b30]            \*\*\*         \*    \*\*
  Hoal *et al*.[@b31]               \*\*\*\*        \*    \*\*
  Bellamy *et al*.[@b32]              \*\*          \*    \*\*

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs1800450 (A \> B) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                          
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------- ------- ------- --------
  B vs. A                      −0.36                  −2.83 to 2.10                      0.75                 34.32   0.002   59.78   Random
  BB vs. AA                    0.69                   −0.86 to 2.24                      0.34                 14.93   0.185   26.34   Fixed
  AB vs. AA                    −0.65                  −3.02 to 1.70                      0.55                 24.53   0.027   47.01   Random
  BB vs. AA + AB               −0.58                  −3.11 to 1.95                      0.62                 28.57   0.008   54.50   Random
  BB + AB vs. AA               −0.65                  −2.14 to 0.82                      0.34                 13.83   0.242   20.50   Fixed

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs1800451 (A \> C) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                          
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------- ------- ------- --------
  C vs. A                      0.64                   −0.58 to 1.87                      0.26                 16.28   0.092   38.58   Fixed
  CC vs. AA                    0.06                   −1.04 to 1.17                      0.88                 3.16    0.788   0.001   Fixed
  CA vs. AA                    0.58                   −0.89 to 2.06                      0.39                 19.21   0.038   47.99   Random
  AA vs. CC + AC               0.66                   −0.75 to 2.09                      0.31                 18.61   0.045   46.28   Random
  AA + AC vs. CC               −0.04                  −1.04 to 0.94                      0.91                 2.58    0.859   0.001   Fixed

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs5030737 (A \> D) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                         
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------ ------- ------- -------
  D vs. A                      −1.77                  −4.75 to 1.21                      0.19                 7.04   0.425   0.57    Fixed
  DD vs. AA                    9.67                  −41.00 to 60.34                     0.49                 1.08   0.781   0.001   Fixed
  AD vs. AA                    −1.80                  −5.48 to 1.87                      0.27                 8.67   0.27    19.27   Fixed
  AA vs. DD + AD               −1.68                  −4.87 to 1.50                      0.24                 6.94   0.43    0.001   Fixed
  AA + AD vs. DD               −9.36                 −62.48 to 43.76                     0.52                 1.15   0.76    0.001   Fixed

###### Statistics to test publication bias and heterogeneity in the present meta-analysis: *MBL2* combined rs1800450, rs1800451, rs5030737 (A \> O) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                          
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------- ------- ------- --------
  O vs. A                      −1.02                  −9.79 to 7.75                      0.79                 89.83   0.001   89.98   Random
  OO vs. AA                    0.76                   −4.59 to 6.12                      0.75                 62.10   0.001   85.50   Random
  AO vs. AA                    0.20                   −7.59 to 8.00                      0.95                 58.38   0.001   84.58   Random
  OO vs. AA + AO               0.98                   −8.03 to 10.00                     0.80                 80.99   0.001   88.88   Random
  OO + AO vs. AA               −0.82                  −5.07 to 3.42                      0.66                 40.76   0.001   77.92   Random

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs7096206 (Y \> X) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                          
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------- ------- ------- --------
  X vs. Y                      2.03                   −2.08 to 6.14                      0.25                 20.14   0.003   70.21   Random
  XX vs. YY                    0.36                   −3.70 to 4.43                      0.82                 7.38    0.287   18.71   Fixed
  XY vs. XX                    2.41                   −1.13 to 5.96                      0.14                 21.66   0.001   72.30   Random
  YY vs. XX + XY               2.22                   −1.64 to 6.10                      0.19                 22.22   0.001   73.00   Random
  YY + XY vs. XX               0.07                   −3.57 to 3.72                      0.95                 5.80    0.446   0.001   Fixed

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs11003125 (H \> L) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                         
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------- ------ ------- --------
  L vs. H                      −0.69                 −15.13 to 13.75                     0.85                 7.39    0.06   59.41   Fixed
  LL vs. HH                    2.59                  −10.78 to 15.97                     0.49                 6.73    0.08   55.45   Fixed
  LH vs. LL                    −1.00                  −10.49 to 8.49                     0.69                 11.71   0.01   74.39   Random
  HH vs. LL + LH               −0.71                  10.65 to 9.22                      0.78                 11.37   0.01   73.61   Random
  HH + LH vs. LL               1.30                   −8.32 to 10.93                     0.61                 3.40    0.33   11.75   Fixed

###### Statistics to test publication bias and heterogeneity in this meta-analysis: *MBL2* rs7095891 (P \> Q) polymorphism.

  Comparisons       Egger's regression analysis   Heterogeneity analysis   Model used for the meta-analysis                        
  ---------------- ----------------------------- ------------------------ ---------------------------------- ------ ------ ------- -------
  Q vs. P                      −0.82                  −3.15 to 1.50                      0.13                 0.89   0.63   0.001   Fixed
  QQ vs. PP                    −0.05                  −4.02 to 3.91                      0.88                 0.17   0.91   0.001   Fixed
  PQ vs. PP                    −0.63                  −2.03 to 0.75                      0.10                 0.41   0.81   0.001   Fixed
  QQ vs. PP + PQ               −0.77                  −2.70 to 1.16                      0.12                 0.63   0.72   0.001   Fixed
  QQ + PQ vs. PP               0.04                   −3.83 to 3.93                      0.90                 0.16   0.92   0.001   Fixed

[^1]: These authors contributed equally to this work.
